Ac­tivists slam Im­munomedics’ $2B deal with Seat­tle Ge­net­ics in the mid­dle of a proxy war

Be­hzad Ag­haz­adeh, ven­Bio

Im­munomedics’ $2 bil­lion deal with Seat­tle Ge­net­ics late last week pro­voked a fresh as­sault from a group of ac­tivist in­vestors out to over­throw man­age­ment at the biotech.

Ven­Bio Ad­vi­sors gath­ered a 9.9% stake in Im­munomedics $IM­MU and charged in­to a bat­tle with the com­pa­ny’s board and top ex­ecs in a nasty squab­ble that’s sparked ac­cu­sa­tions of ly­ing and cheat­ing as the ac­tivists an­gled to get their 4 can­di­dates elect­ed to the Im­munomedics board.

Then on Fri­day Seat­tle Ge­net­ics un­veiled their deal to ac­quire con­trol of Im­munomedics’ sol­id tu­mor drug IM­MU-132 with $300 mil­lion in near-term cash and $1.7 bil­lion in mile­stones. Im­munomedics then said it was post­pon­ing its an­nu­al meet­ing so that its in­vestors could con­sid­er the con­se­quences of the deal.

In lit­tle time ven­Bio hit back at the “seem­ing­ly poor deal,” crit­i­ciz­ing a short go-shop pe­ri­od to see if any­one would like to bid high­er. Seat­tle Ge­net­ics al­so got a sweet­heart deal to buy the com­pa­ny’s stock at a big dis­count, ven­Bio claimed, and in­vestors are like­ly to get hit by a de­cline in share price af­ter ex­ecs gave away the com­pa­ny’s crown jew­el.

There was no im­me­di­ate re­sponse from Im­munomedics.

Dr. Be­hzad Ag­haz­adeh, Man­ag­ing Part­ner and port­fo­lio man­ag­er at ven­Bio, said:

“Im­munomedics’ an­nounce­ment of a deal with Seat­tle Ge­net­ics is a bla­tant and shame­ful ma­neu­ver by the cur­rent Board and man­age­ment to ma­nip­u­late the out­come of the up­com­ing An­nu­al Meet­ing and en­trench them­selves at the ex­pense of stock­hold­ers’ best in­ter­ests, and ven­Bio is ex­plor­ing all op­tions to hold them ac­count­able. The cur­rent Board’s at­tempt to claim that the tim­ing of this part­ner­ship – four busi­ness days be­fore the An­nu­al Meet­ing – is co­in­ci­den­tal and was mo­ti­vat­ed pure­ly by a de­sire to iden­ti­fy the best deal is pre­pos­ter­ous and clear­ly disin­gen­u­ous, in our view, es­pe­cial­ly when they have agreed to an aber­rant­ly short six busi­ness day go-shop pe­ri­od.”

Qual­i­ty Con­trol in Cell and Gene Ther­a­py – What’s Re­al­ly at Stake?

In early 2021, Bluebird Bio was forced to suspend clinical trials of its gene therapy for sickle cell disease after two patients in the trial developed cancer. As company scientists rushed to assess whether there was any causal link between the therapy and the cancer cases, Bluebird’s stock value plummeted – as did those of multiple other biopharma companies developing similar therapies.

While investigations concluded that the gene therapy was unlikely to have caused cancer, investors and the public may be more skittish regarding the safety of gene and cell therapies after this episode. This recent example highlights how delicate the fields of cell and gene therapy remain today, even as they show great promise.

Chris Gibson (Photo By Vaughn Ridley/Sportsfile for Web Summit via Getty Images)

Re­cur­sion founders gin for­tunes as IPO back­ers show­er $436M on one of the biggest boasts in AI -- based on some very small deals

In the AI drug development world, boasting often comes with the territory. Yet few can rival Recursion when it comes to claiming the lead role in what company execs like to call the industrialization of drug development, with promises of continued exponential growth in the number of drugs it has in the pipeline.

On Friday, the Salt Lake City-based biotech translated its unicorn-sized boasts into a killer IPO, pricing more than 24 million shares at the high end of its range and bringing in $436 million — with a large chunk of that promised by some deep-pocket backers.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

UP­DAT­ED: New Kaiser analy­sis shows how lim­it­ing price ne­go­ti­a­tions to tar­get­ed drugs may bet­ter fo­cus up­com­ing leg­is­la­tion

As Congress considers whether to adopt sweeping new legislation to lower prescription drug prices across the board, the Kaiser Family Foundation is out with a new report on Monday showing how a more targeted approach on a subset of drugs might be a more efficient way to save government funds.

“This analysis shows that Medicare Part D and Part B spending is highly concentrated among a relatively small share of covered drugs, mainly those without generic or biosimilar competitors,” wrote Juliette Cubanski, deputy director of the program on Medicare policy at KFF, and Tricia Neuman, SVP of KFF. “Focusing drug price negotiation or reference pricing on a subset of drugs that account for a disproportionate share of spending would be an efficient use of administrative resources, though it would also leave some potential savings on the table.”

When is a drug re­al­ly a de­vice? Court knocks down FDA ap­peal in try­ing to sort that grey area

It’s always a surprise when a court has to step in to tell the FDA that it erred in performing one of its main duties: classifying whether a medical product is drug or a device.

But that’s what the US Court of Appeals for the District of Columbia did on Friday, making clear to the world’s top drug regulator that Genus Medical Technologies’ contrast agent barium sulfate (also known as Vanilla SilQ) should not be considered a drug, as the FDA had said, but a medical device.

Tillman Gerngross (Adagio)

Till­man Gern­gross' Covid-19 an­ti­body moon­shot scores $336M with the help of new ace CFO. Is an IPO next?

Less than a year into its existence, serial biotech entrepreneur Tillman Gerngross’ antibody play Adagio has raced ahead into a pivotal trial for its lead drug for Covid-19 on the back of some very promising preclinical data. Now, crossover investors led by Peter Kolchinsky at RA are rolling up the Brinks truck — and that could spell an IPO in the offing for Adagio.

Adagio has bagged $336 million as part of a Series C round led by RA Capital to advance lead single-shot antibody ADG20 through a pivotal Phase I/II/III trial for the treatment of mild to moderate Covid-19 patients at high risk of infection, the biotech said Monday.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 107,200+ biopharma pros reading Endpoints daily — and it's free.

Q1: A flood of in­vestor cash drove biotech's num­bers to new record highs, and the tor­rent of cash is mov­ing up­stream fast

If you thought biotech was booming last year, wait until you get a load of the numbers from Q1 2021.

On virtually every level, with one exception, the money engine was working around the clock in the first 3 months of this year. Venture capital has reached such a fever peak that the average B round now weighs in at an average mega-weight value of $100 million. The money flow is also finding its way to the mouth of the R&D river, where discovery work now merits the big bucks instead of cautionary seed funds.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Jami Rubin (EQRx)

Ja­mi Ru­bin, once fa­bled for grilling bio­phar­ma ex­ecs, de­camps to head fi­nance at drug pric­ing dis­rupter

As Goldman Sachs’ top pharmaceutical analyst, Jami Rubin was known for asking the tough questions. Now, as she takes the lead on EQRx’s mission to rewrite the rules of drug pricing, we’ll see how good her answers are.

Rubin made the jump to biotech on April 5, becoming EQRx’s new CFO, the company said Monday. She’s coming from PJT Partners, where she’s been a partner providing strategic guidance for biotech and pharmaceutical companies for the last couple years. With EQRx’s recent $500 million Series B round in the books, it wouldn’t be a surprise if she was already lining up a public debut.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 107,200+ biopharma pros reading Endpoints daily — and it's free.

Seagen gets Au­gust PDU­FA for Pad­cev ex­pan­sions; Adap­tate pulls in new cash for gam­ma delta T cell an­ti­bod­ies

Seagen is riding the wave of two new priority reviews straight to the FDA.

The Bothell, WA-based biotech and their partners at Astellas announced Monday that two supplemental BLAs for Padcev had been accepted by US regulators. FDA has set Aug. 17 as the PDUFA date for the reviews.

“With our recent regulatory submissions, we intend to provide the highest level of clinical evidence supporting Padcev use — overall survival data from a randomized Phase III trial — and expand availability in multiple countries where there is unmet medical need,” said Astellas oncology chief Andrew Krivoshik.

Ben Carson (Evan Vucci, AP Images)

UP­DAT­ED The doc­tor is in: Trump in­sid­er Ben Car­son joins NASH play­er Galectin as a 'spe­cial con­sul­tant,' part-time spokesman

In the few short months since President Donald Trump left office, his former department heads are reportedly having a difficult time finding employment. But for Ben Carson, Trump’s former housing secretary, that’s not a problem anymore after biotech came calling.

Carson, a former GOP presidential candidate and erstwhile HUD head, has joined Galectin Therapeutics as a “special consultant” the biotech hopes will help raise its profile and provide an entrée to key business partnerships, the company said Monday.